The original success of the copyright undeniably revolutionized the medication landscape, but investing in companies primarily reliant on unbranded versions presents a uncertain picture. Despite early returns were impressive, the cessation of patents and the appearance of less expensive alternatives have eroded the customer base. Thus, a thorough e